Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281495 · ClinicalTrials.gov registry record · Phase 2
Taldefgrobep Alfa in Adults With Overweight and Obesity
A Phase 2 study of Obesity and Overweight, sponsored by Biohaven Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT07281495 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Biohaven Therapeutics. The registered enrollment target is 150 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT07281495, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Biohaven Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Taldefgrobep Alfa
Study Locations (20)
California
- Site-001 - Chula Vista
- Site-014 - Montclair
- Site-011 - Sacramento
- Site-018 - Tustin
Florida
- Site-020 - Orlando
- Site-008 - Palm Springs
- Site-015 - St. Petersburg
Texas
- Site-005 - Austin
- Site-012 - McKinney
- Site-013 - San Antonio
Louisiana
- Site-010 - Baton Rouge
- Site-009 - Metairie
Missouri
- Site-006 - City of Saint Peters
- Site-003 - Springfield
Illinois
- Site-007 - Chicago
Indiana
- Site-016 - Indianapolis
North Carolina
- Site-019 - Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281495
The ClinicalTrials.gov registry entry for NCT07281495 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07281495 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07281495 about?
NCT07281495 is a clinical study titled "Taldefgrobep Alfa in Adults With Overweight and Obesity". This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
What is the current status of trial NCT07281495?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-11-24. Estimated completion is 2026-09.
What conditions does trial NCT07281495 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07281495?
The interventions under investigation include: Placebo (DRUG), Taldefgrobep Alfa (DRUG).
Who is sponsoring clinical trial NCT07281495?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281495 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.